Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,974 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06641791RecruitingPhase 3
Comparing two radiation approaches for advanced head and neck cancer
This trial compares two types of radiation therapy to relieve symptoms from advanced head and neck cancer that cannot be cured. One is a shorter, more precise treatment (SBRT), and the other is standard radiation. The goal is to see which better improves quality of life and reduces side effects.
Calgary, AlbertaAges 18 years+ - NCT05533697RecruitingPhase 1/Phase 2
mRNA medicine with or without immunotherapy for advanced solid cancers
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
Los Angeles, CaliforniaAges 12 years+ - NCT04090567RecruitingPhase 2
Olaparib with two partners for advanced BRCA breast cancer
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Houston, TexasAges 18 years+ - NCT04092660Recruiting
Mouth guard study to reduce airway collapse in sleep apnea
This study tests whether using an anti-snoring mouth guard (a mandibular advancement appliance) can help keep your airway open during sleep if you have obstructive sleep apnea. If you’re referred for this kind of mouth guard, the trial will see if using it more regularly or in a specific way improves symptoms or breathing during sleep.
LondonAges 40–90 - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Tampa, FloridaAges 18 years+ - NCT04145622RecruitingPhase 1/Phase 2
Ifinatamab deruxtecan for advanced hard-to-treat solid cancers
This early-stage trial tests an investigational antibody-drug medicine (ifinatamab deruxtecan) in people with advanced solid tumors. It aims to see whether it can shrink tumors or help control cancer, and to learn about side effects and the best way to use it.
Los Angeles, CaliforniaAges 18 years+ - NCT04146298RecruitingPhase 1/Phase 2
KRAS-mutant pancreatic cancer T-cell therapy for some people
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
ShanghaiAges 18–75 - NCT04216732Recruiting
Study of medullary thyroid cancer progression in a registry
This study follows people with medullary thyroid cancer to better understand how the disease changes over time, including in advanced stages. You may help improve future treatment planning and care for people with medullary thyroid cancer.
San Francisco, CaliforniaAges 18 years+ - NCT04503265RecruitingPhase 1/Phase 2
AMXI-5001 study for advanced cancers that won’t respond
This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT04515810Recruiting
Mobile app coaching for planning care after serious cancer
This study tests a mobile health app (PACT) to help people with advanced cancer talk and plan for future care. It may help you and a loved one stay engaged in advance care planning (planning what care you want and who should speak for you).
Manhasset, New YorkAges 18 years+ - NCT04570943RecruitingPhase 2
Pancreatic cancer treatment: chemo first, then targeted MRI-guided radiation
This Phase 2 trial tests giving specific chemotherapy in sequence, then using MRI-guided focused radiation to treat locally advanced, non-removable pancreatic cancer. It may help shrink or control the tumor while aiming radiation more precisely using MRI.
Marseille, Bouches-du-RhôneAges 18–75 - NCT04617522RecruitingPhase 1
Sacituzumab govitecan for advanced cancers with moderate liver issues
This Phase 1 study tests how safe and tolerable sacituzumab govitecan is for people with advanced or metastatic solid tumors who also have moderate liver impairment. It aims to find the right dosing so the treatment can be used more safely in this liver-risk group.
Long Beach, CaliforniaAges 18 years+ - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT04686305RecruitingPhase 1
Test drug T-DXd plus immunotherapy, with or without chemotherapy for HER2+ lung cancer
This Phase 1 study tests the safety (and early effectiveness) of T-DXd combined with immunotherapy, sometimes also with chemotherapy, in people with advanced lung cancer that is HER2-positive. It may help if standard options have been limited or your tumor does not have certain genetic changes that already have targeted treatments.
Duarte, CaliforniaAges 18 years+ - NCT04693468RecruitingPhase 1
Testing three combinations for advanced solid tumors with gene defects
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
Houston, TexasAges 18 years+ - NCT04694924Recruiting
Prostate cancer patient registry to track experiences
This study builds a database of people with localized or locally advanced prostate cancer to better understand patient-reported outcomes (your experiences and quality-of-life). It may help improve future care by collecting consistent feedback from patients.
Dendermonde, Oost-VlaanderenAges 18 years+ - NCT04740424RecruitingPhase 1
First study of a new drug for advanced solid cancers
This Phase 1 trial tests a brand-new treatment (given at increasing doses) for people with advanced, unresectable, or metastatic solid tumors. It mainly looks at safety and how the drug behaves in the body, and it may help if standard treatments didn’t work or aren’t suitable.
Waratah, New South WalesAges 18 years+ - NCT04749108RecruitingPhase 2/Phase 3
Tailored treatment for locally advanced rectal cancer after FOLFIRINOX
This trial studies a more customized treatment plan for people with locally advanced rectal (bowel) cancer after they receive FOLFIRINOX chemotherapy. It aims to reduce tumor spread risk and improve outcomes by tailoring the next steps based on scan details and your health status.
Marseille, Bouches Du RhôneAges 18 years+ - NCT04752826RecruitingPhase 1/Phase 2
Testing BI-1808 plus Keytruda for advanced cancers
This trial tests a new cancer medicine (BI-1808) either alone or together with Keytruda (pembrolizumab) in people with advanced cancers. It may help by strengthening the immune system’s attack on cancer, especially if standard treatments are no longer working or aren’t suitable.
Duarte, CaliforniaAges 18 years+ - NCT04757337RecruitingPhase 3
Oral chemotherapy comparison for older advanced soft-tissue cancer
This trial compares two chemotherapy medicines—oral cyclophosphamide versus doxorubicin—in people age 65 and older with advanced soft-tissue sarcoma that can’t be cured with surgery or radiation. It aims to see which treatment works better and is more tolerable for this age group.
ToulouseAges 65 years+ - NCT04762199RecruitingPhase 1
MRX-2843 with osimertinib for EGFR-mutant lung cancer
This Phase 1 study tests whether combining MRX-2843 with osimertinib can help control advanced lung cancer that has specific EGFR gene changes. It is designed to find the safest dose and check early signs of tumor response.
Atlanta, GeorgiaAges 18 years+ - NCT04777994RecruitingPhase 1
Drug ABBV-CLS-484 for advanced cancers that lack options
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Tucson, ArizonaAges 18 years+ - NCT04778839RecruitingPhase 1
Paclitaxel drug in tiny “micelles” for advanced solid cancers
This Phase 1 trial tests a chemotherapy drug called paclitaxel in a special “micelle” form in people with advanced solid tumors. It’s mainly designed to check safety and dosing, and it may help shrink tumors in people who don’t have good standard treatment options.
Hanzhou, ZhejiangAges 18–70 - NCT04827810RecruitingPhase 1
IV gamitrinib study for advanced cancers needing new options
This early-phase trial tests how safe IV gamitrinib is and how the body processes it in people with advanced cancers that can’t be controlled by standard treatment. It may also help researchers learn the best dose and whether it has signs of anti-cancer activity.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,974 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.